Multiple lines of evidence suggest that the ACE DD genotype is associated with reduced renal benefit from ACE inhibitor treatment in patients with type 1 or type 2 diabetic nephropathy [247, 261]. The gene discussed is ACE; the disease is type 2 diabetes nephropathy.